Randomized study of bevacizumab/Tarceva [erlotinib] and Tarceva/Sulindac in squamous cell carcinoma of the head and neck.

Trial Profile

Randomized study of bevacizumab/Tarceva [erlotinib] and Tarceva/Sulindac in squamous cell carcinoma of the head and neck.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2017

At a glance

  • Drugs Erlotinib (Primary) ; Bevacizumab; Sulindac
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jan 2017 Status changed from completed to discontinued due to slow accrual.
    • 12 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 06 Mar 2012 Planned end date changed from 1 Oct 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top